[Pharmacokinetics of gadolinium-DTPA in chronic renal insufficiency requiring dialysis].
MRT with gadolinium-DTPA (0.1 mmol/kg body weight) was performed in 10 patients with renal insufficiency requiring dialysis and the clearance of gadolinium-DTPA was studied. After 3 dialysis on 3 successive days more than 97% of the initial concentration of gadolinium-DTPA had been eliminated. Average half-life was 1.87 hours. There were no side effects in any of the patients. Close laboratory observation of liver function showed no significant changes during the period of study. No contra-indication for the use of this contrast medium in patients with renal insufficiency requiring dialysis was found during this study.
Krahe
T
T
Institut für Röntgendiagnostik, Universität Würzburg.
Götz
R
R
Lackner
K
K
Haustein
J
J
Klemenz
U
U
Landwehr
P
P
Heidbreder
E
E
Schuhmann-Giampieri
G
G
D000328:Adult; D000368:Aged; D003287:Contrast Media / Q000493:pharmacokinetics*; D005260:Female; D019786:Gadolinium DTPA; D006801:Humans; D007676:Kidney Failure, Chronic / Q000175:diagnosis / Q000378:metabolism* / Q000628:therapy; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009942:Organometallic Compounds / Q000493:pharmacokinetics*; D004369:Pentetic Acid / Q000493:pharmacokinetics*; D006435:Renal Dialysis
D003287:Contrast Media; D009942:Organometallic Compounds; D004369:Pentetic Acid; D019786:Gadolinium DTPA
Pharmakokinetik von Gadolinium-DTPA bei dialysepflichtiger chronischer Niereninsuffizienz.